(2026). Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: A Phase 1, randomized, single ascending dose escalation study in healthy participants. PLOS Neglected Tropical Diseases Atom.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Safety and Pharmacokinetics of GSK3494245, a Highly Selective Leishmaniasis Kinetoplastid Proteasome Inhibitor for the Treatment of Visceral Leishmaniasis: A Phase 1, Randomized, Single Ascending Dose Escalation Study in Healthy Participants."
PLOS Neglected Tropical Diseases Atom 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Safety and Pharmacokinetics of GSK3494245, a Highly Selective Leishmaniasis Kinetoplastid Proteasome Inhibitor for the Treatment of Visceral Leishmaniasis: A Phase 1, Randomized, Single Ascending Dose Escalation Study in Healthy Participants."
PLOS Neglected Tropical Diseases Atom, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.